ArticleMovement disorders clinical practice2025
Effects of Levodopa on Gait in People With Parkinson's Disease With and Without a History of Falls.
Article in Movement disorders clinical practice, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Sarcopenia, body composition, physical performance, and clinical features in Parkinson's disease: a cross-sectional comparative study.Frontiers in endocrinology · 2026Article
- Effects of anti-parkinsonian medication on gait during internal and external rhythmic auditory cueing in PD.Frontiers in human neuroscience · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
backgroundThe impact of levodopa on gait in individuals with Parkinson's disease (PD), particularly in those with and without a history of falls, remains unclear.
objectiveThis study examines whether levodopa alters digital gait characteristics in fallers and non-fallers with PD to those observed in healthy controls (HC) and identifies key gait and turning measures most influenced by levodopa.
methodsWe recruited 33 individuals with PD (17 fallers, 16 non-fallers) and 17 HC. Participants wore six inertial sensors on both wrists, feet, lumbar region (L5), and sternum while performing a walking test in Off and On levodopa states. Seventeen digital gait measures were extracted, and responsiveness to levodopa was assessed using standardized response means (SRM).
resultsFallers exhibited greater turning impairments Off levodopa than non-fallers. Levodopa significantly improved nearly all gait measures in both groups, normalizing them to HC levels. It had a strong effect on gait (fallers: highest |SRM| = 1.32; non-fallers: highest |SRM| = 0.94). In fallers, turn velocity, toe-off angle, gait speed, and stride length showed the most improvement (|SRM| >1). Non-fallers showed the greatest improvements in trunk coronal range of motion (ROM), arm swing velocity, arm ROM, and turn velocity (|SRM| >0.8). Fallers had worse patient-reported outcomes and balance test scores, but no significant differences in UPDRS Part III, and Hoehn and Yahr scores.
conclusionsThese findings suggest that impaired turning and gait shuffling in PD may be associated with falls and that dopamine replacement therapy, as well as rehabilitation, focused on improving turning and gait shuffling may reduce fall risk.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.